Hence, pharmacological CDK2 inhibitors (which are already available) might not be ideal candidates for HCC therapy, while direct targeting of CCNE1 could be a very promising approach by disrupting CDK2-dependent and independent oncogenic functions. This evidence concerns the gene CCNE1 and hepatocellular carcinoma.